Addressing the inter-individual variation in response to consumption of plant food bioactives: Towards a better understanding of their role in healthy aging and cardiometabolic risk reduction. by Manach, Claudine et al.
1600557 (1 of 16) Mol. Nutr. Food Res. 61, 6, 2017, 1600557DOI 10.1002/mnfr.201600557
REVIEW
Addressing the inter-individual variation in response to
consumption of plant food bioactives: Towards a better
understanding of their role in healthy aging and
cardiometabolic risk reduction
Claudine Manach1∗, Dragan Milenkovic1∗, Tom Van de Wiele2, Ana Rodriguez-Mateos3,
Baukje de Roos4, Maria Teresa Garcia-Conesa5, Rikard Landberg6,7, Eileen R. Gibney8,
Marina Heinonen9, Francisco Toma´s-Barbera´n5 and Christine Morand1
1 INRA, UMR 1019, UNH, CRNH Auvergne, F-63000 Clermont-Ferrand; Clermont Universite´, Universite´ d’Auvergne,
Unite´ de Nutrition Humaine, BP 10448, F-63000, Clermont-Ferrand, France
2 Center for Microbial Ecology and Technology (CMET), Ghent University, Ghent, Belgium
3 Division of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, University of Du¨sseldorf, Germany
4 Rowett Institute of Nutrition and Health, University of Aberdeen, Aberdeen, UK
5 Research Group on Quality, Safety and Bioactivity of Plant Foods, CEBAS-CSIC, Campus de Espinardo, Murcia,
Spain
6 Department of Food Science, Swedish University of Agricultural Sciences, Uppsala, Sweden
7 Nutritional Epidemiology Unit, Institute of Environmental Medicine, Karolinska Institutet, Solna, Sweden
8 UCD Institute of Food and Health, University College Dublin, Dublin, Republic of Ireland
9 Department of Food and Environmental Sciences, Food Chemistry, University of Helsinki, Finland
Received: July 3, 2016
Revised: September 8, 2016
Accepted: September 13, 2016
Bioactive compounds in plant-based foods have health properties that contribute to the preven-
tion of age-related chronic diseases, particularly cardiometabolic disorders. Conclusive proof
and understanding of these benefits in humans is essential in order to provide effective dietary
recommendations but, so far, the evidence obtained from human intervention trials is limited
and contradictory. This is partly due to differences between individuals in the absorption, distri-
bution, metabolism and excretion of bioactive compounds, as well as to heterogeneity in their
biological response regarding cardiometabolic health outcomes. Identifying the main factors
underlying inter-individual differences, as well as developing new and innovative methodolo-
gies to account for such variability constitute an overarching goal to ultimately optimize the
beneficial health effects of plant food bioactives for each and every one of us. In this respect, this
position paper from the COSTAction FA1403-POSITIVe examines themain factors likely to af-
fect the individual responses to consumption of plant food bioactives and presents perspectives
for assessment and consideration of inter-individual variability.
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1 Introduction
Cardiometabolic disease, which comprises cardiovascular
diseases, type 2 diabetes mellitus and their associated risk
factors including metabolic syndrome and obesity, is the
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world’s leading cause of death and a major public health
concern. Observational studies provide convincing evidence
that most cases of cardiometabolic disease could be avoided
through dietary and lifestyle changes [1,2]. It is therefore nec-
essary to establish effective preventive strategies targeting
physical activity, smoking patterns, and dietary behaviours of
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Figure 1. Potential factors re-
sponsible for inter-individual
variability in bioavailability and
biological responsiveness to
consumption of plant food
bioactives in relation to car-
diometabolic health.
populations and to drive the food industry to produce health-
ier foods.
A high intake of plant-based foods has shown beneficial
effects on cardiometabolic health, both in large population
studies [3–6] and randomized controlled trials [7–9]. Plant-
based foods typically have a low caloric density and provide a
range of beneficial nutrients and low-energetic constituents,
such as dietary fibres, essential vitamins and minerals, and
are exclusive and rich sources of a wide variety of phyto-
chemicals, including polyphenols, carotenoids, plant sterols,
and glucosinolates. Although not strictly essential micronu-
trients, some phytochemicals have been described as “lifes-
pan essential”, as they promote optimal health during age-
ing [10]. There is increasing evidence from cohort studies
and randomized controlled trials that many of these bioactive
compounds may help to reduce the risk of chronic diseases,
particularly of cardiometabolic diseases [11–13]. Plant food
bioactives arewidely distributed in the diet but specific groups
of compounds can be particularly abundant in some foods for
which specific dietary recommendations may be developed:
e.g. glucosinolates in cruciferous vegetables, isoflavones in
soya, anthocyanins in berries or lycopene in tomatoes. Spe-
cific physiological effects with implications for health have
been attributed to different bioactive compounds. For exam-
ple, polyphenol-rich foods and beverages can improve en-
dothelial function, platelet function, insulin sensitivity and
decrease blood pressure [14–16]. In 2012, the European Food
Safety Authority (EFSA) panel onDietetic Products, Nutrition
and Allergies has approved a health claim related to cocoa fla-
vanols and maintenance of normal endothelium-dependent
vasodilation, according to regulation (EC) No 1924/2006 [17].
Despite intense and active research investigating the health
effects of plant food bioactives over the last years, the real
impact of most compounds and their mechanisms of action
have not yet been fully elucidated. Plant food bioactives have
been shown to exert antioxidant, anti-inflammatory, anti-
atherogenic activities through a large panel of mechanisms,
including modulation of enzyme activities, binding to cell
receptors and interfering with signalling pathways and tran-
scription factors ultimately regulating gene expression, alter-
ing DNA methylation or affecting the gut microbial popula-
tion and functionality [18–21].
An increasing number of studies investigating the health
effects of plant food bioactives have revealed substantial
between-subject variations in response to dietary interven-
tions, suggesting that the consumption of particular foods or
bioactive constituents may benefit some individuals more
than others. The major determinants responsible for the
between-subject variability may include genetic and non-
genetic factors which are only beginning to be explored and
may differ depending on the compounds (Fig. 1). The aim of
this position paper is to highlight the complexity of this issue
and the need of increasing knowledge in the field, both to
better understand the contribution of phytochemicals in the
health effects of plant-based foods and to develop effective
strategies and refined dietary recommendations to optimize
the beneficial effects of bioactive-containing foods for all pop-
ulation groups.
1.1 Inter-individual variation in metabolism and
bioavailability of plant food bioactives
After decades of active research, much about the absorption,
distribution, metabolism, and excretion (ADME) patterns of
the main plant food bioactives is now known and has been
reviewed in humans [22–24]. However, key information on
many of the enzymes, carrier proteins or bacterial strains
critical for the absorption and metabolism of these bioactive
compounds and the factors that may modulate their activi-
ties is still lacking. Some plant bioactives can be absorbed
in their native form from the stomach or gut, but most of
the glycosylated, polymeric, or esterified native plant com-
pounds have to be hydrolyzed before absorption, a step partly
C© 2016 The Authors. Molecular Nutrition & Food Research published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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carried out by the gut microbiota [25]. The specific bacterial
strains responsible for this initial hydrolysis have not been
extensively studied yet. For the intestinal uptake of the bioac-
tive compounds both passive and active mechanisms have
been described, as well as efflux transporters that lower the
absolute influx of bioactives through the intestinal absorp-
tion. Nevertheless, our knowledge of the carriers involved
for the various compounds is still very sparse. When ab-
sorbed, hydrophilic plant food bioactives typically undergo
first pass metabolism in the intestine and in the liver with
phase I (oxidation/reduction reactions) and mainly phase II
(-glucuronidation, sulfation, methylation, glutathione con-
jugation) biotransformations [22]. A substantial enterohep-
atic recirculation exists for some metabolites. Lipophilic
bioactive compoundsmay be absorbed through the lymphatic
system and thereby escape the first pass metabolism by the
liver. For anumber of plant foodbioactives, the gutmicrobiota
in addition to the intestine and liver handles the production
of a wide range of metabolites, which can bemore or less spe-
cific of their precursors [26]. The gutmicrobiota composition,
specific bacteria strains and the functionalities responsible
for all these metabolic biotransformations, as well as their
occurrence and distribution in humans have not been exten-
sively investigated. Further research in this specific area will
be essential for a better understanding of the inter-individual
variation.
In human intervention studies that target the bioavail-
ability of diverse plant food bioactives or in large-scale ob-
servational studies, researchers consistently observed that
the plasma concentrations and urinary excretion levels of
plant bioactives or their derived metabolites can markedly
differ between individuals upon a similar dietary intake. Sev-
eral examples of clinical intervention studies that demon-
strated inter-individual variability in bioavailability of differ-
ent families of plant food bioactives are presented in Table 1
[27–41]. However, a systematic analysis of the magnitude of
this inter-individual variability has not been performed so
far. Between-subject differences could arise due to variances
in absorption, metabolism, tissue distribution and turnover,
excretion or a combination of these parameters. This has
been clearly demonstrated for carotenoids and has led re-
searchers to propose that some subjects could be considered
“non-responders” to carotenoids on the basis of their low
plasma concentration after intake [42]. Several studies re-
cently demonstrated an association between the carotenoid
status and variants of genes encoding proteins involved in
the absorption and metabolism of carotenoids. These in-
clude SR-BI (Scavenger Receptor Class B, Member 1) and
CD36 (CD36 Molecule, Thrombospondin Receptor) both
involved in the uptake of carotenoids by intestinal cells,
as well as BCO1 (Beta-Carotene Oxygenase 1) which cat-
alyzes the oxidative cleavage of carotenoids into vitamin-A
[43, 44].
In addition, it is most likely that host genetic and epi-
genetic variations in metabolizing enzymes can be a major
determinant of individual phenotypes. Pharmacogenomics
studies have demonstrated that for particular drugs, includ-
ing some phytochemicals of the alkaloid family like codeine,
individuals can be categorized into poor, intermediate or
extensive and ultra-rapid metabolizers and dosing has to be
adapted to achieve equivalent plasma or tissue concentration
of the active metabolite [45]. Differences have been attributed
to specific genes and enzymes of the xenobiotic metabolism
pathways and the genetic variants associated have been
compiled in online databases such as the Pharmacogenomics
knowledgebase (PharmGKB) [46] and on the FDA Table of
Pharmacogenomic Biomarkers in Drug Labeling (http://
www.fda.gov/Drugs/ScienceResearch/ResearchAreas/
Pharmacogenetics/ucm083378.htm, accessed 26/08/16).
Most plant food bioactives are absorbed and metabolized
through the same polymorphic carriers and enzymatic
systems as some of these drugs, and their pharmacokinet-
ics is thus also likely to depend on genetic background.
Caffeine is a plant bioactive for which the importance of
genetic polymorphisms has been demonstrated. It is mainly
metabolized by CYP1A2 in the liver. Subjects with the
CYP1A2*1F variant (carriers of the -163 C allele) associated
with a low enzyme inducibility are considered to be slow
caffeine metabolizers in comparison with the rapid caffeine
metabolizers carrying the wild-type allele [47]. Slow caffeine
metabolizers have been shown to be at increased risk of
hypertension and myocardial infarction, whereas for rapid
caffeine metabolizers it might be more safe to drink coffee
[48]. Plant food bioactives are also extensively metabolized
by phase II conjugation enzymes. Several variants exist for
genes encoding glutathione S-transferases (GSTs), which
play an important role in the metabolism of glucosinolates
present in cruciferous vegetables. After broccoli consump-
tion, the bioavailability of isothiocyanates was shown to be
20% higher in GSTM1 null subjects than in GSTM1 positive
subjects [30]. This is of significance as the prevalence of the
null allele for GSTM1 has been estimated to be 40–60% [49].
Variants of UDP-glucuronosyltransferases, sulfotransferases
and catechol-O-methyltransferase, may also contribute to
variability in plant food bioactives metabolism, clearance and
efficacy although it is less documented [50]. The tissue:blood
partition and the excretion kinetics of the metabolites
produced, for example glucuronides, is likely to be different
from that of the native compounds due to differences in
compound polarity. The modulation of phase II enzymes
may thus affect the duration of exposure to bioactive
metabolites and consequently the biological response.
Gut microbiota obviously plays an important role in inter-
individual variation in the metabolism of some plant bioac-
tives. A well-known example is the conversion of the soy
isoflavones daidzin/daidzein into equol by the gutmicrobiota.
Only 25–35% of the Western population and up to 50–70%
of the vegetarian and Asian populations possess the ability
to produce equol from these precursors [36], and producers
have been reported to experience more beneficial health ef-
fects from soy consumption than equol non-producers [51–
53]. The equol-producing bacteria identified so far include
C© 2016 The Authors. Molecular Nutrition & Food Research published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Adlercreutzia, Eggerthella, Paraeggerthella, and Slackia species
all of thembelonging to the family Coriobacteriaceae, a family
that has been associated with beneficial metabolic processes
for obesity and diabetes [54]. Different combinations of bac-
teria can perform the successive steps of the conversion of
soy isoflavones into equol, but the determinants that govern
the daidzein-metabolizing phenotype are not elucidated yet.
Identification of these determinants may lead to the develop-
ment of intervention strategies or food processes to stimulate
equol production in equol non-producers. The gut micro-
biota also play an important role in explaining the variability
in the metabolism of other plant food bioactives, in particu-
lar lignans [55] and ellagitannins [56,57]. Recent advances in
metagenomics, and increased knowledge of the intestinalmi-
crobiota, open up new perspectives to further investigate the
implication of the microbiota in the inter-individual variation
of the bioavailability of plant food bioactives. The European
MetaHit project (FP7, http://www.metahit.eu/) proposed that
themicrobial communities could be classified into threemain
enterotypes characterised by the predominant bacterial pop-
ulation: Bacteroides (enterotype 1), Prevotella (enterotype 2)
and Ruminococcus (enterotype 3) [58]. While it is nowadays
clear that the enterotype concept follows a continuum rather
than discrete values, it must be emphasized that a functional
stratification, rather than a phylogenetic stratification in mi-
crobiome profile also needs to be made [59]. Enterotypes
as well as functionality differences in microbiota (putatively
grouped in “metabotypes”) may be both important for ex-
plaining the inter-individual variation in plant bioactives
ADME and putative health effects as well as for stratifying
subjects [60]. Furthermore, the extent to which dietary inter-
ventions can modulate the gut microbiota and consequently
affect the metabolism of plant food bioactives will have to be
determined.
Besides genetic background and gut microbiota composi-
tion, other factors such as sex, age, dietary habits, may affect
the bioavailability of plant food bioactives. For example, sex-
dependent differences in the glucuronidation of resveratrol,
a polyphenol present in grapes and wine, may be explained
by sex-specific UDP-glucuronosyltransferase isoenzyme ex-
pression profiles regulated by sex hormones [61]. Important
pharmacokinetic changes are known to occur with aging, for
example the volume of distribution is reduced for polar com-
pounds resulting in higher plasma concentrations [62]. How
these changes may affect plant food bioactive ADME needs
to be investigated in details. Dietary habits are known to in-
fluence microbiota diversity and activity [63]. Furthermore,
some dietary phytochemicals such as polyphenols and glu-
cosinolates themselves can induce or inhibit the activity of
phase I and phase II enzymes [50].
As illustrated by the examples above, there is a body of ev-
idence that various factors can control the bioavailability and
metabolism of plant food bioactives in individuals. These fac-
torsmust now be studied in amore systematic and integrative
way to determine their relative importance for each family of
plant food bioactives.
1.2 Inter-individual variation in biological response
regarding cardiometabolic health outcomes
Compared with the inter-individual variation in ADME and
bioavailability, the inter-individual variation in efficacy of
plant food bioactives to modulate physiological outcomes has
been less studied. The etiological basis for this variability
has rarely been considered and individual data are seldom
published. The biological effects of plant food bioactives that
might be occurring only in a subgroup of subjects can be
overlooked when data are averaged for an entire sample pop-
ulation without an appropriate stratification of the partici-
pants. Several clinical intervention studies describing inter-
individual variability in the bioactivity of plant food bioactives
and the associated determinants are presented in Table 2.
For example, in post-menopausal women, consumption of
soy isoflavones resulted in decreased systolic and diastolic
blood pressure and improvement of the endothelial function,
but only in 30% of the volunteers taking part in the study and
who were also found to be equol producers [64]. The effect
would not have been observed when just considering average
values. Similarly, a recent clinical trial which prospectively
recruited male equol producers and non-equol producers
with moderate cardiovascular disease risk, provided evidence
of the importance of the equol phenotype, and thereby of
the gut microbial activity in mediating the positive effect of
dietary isoflavones on arterial stiffness [53]. This would sug-
gest a clear link between bioavailability and efficacy of plant
bioactives but this is not necessarily the case. Indeed, a recent
controlled clinical trial showed that consumption of flavan-3-
ol-enriched dark chocolate resulted in decreased platelet ag-
gregation in males but not females volunteers, however this
effect could not be correlated with plasma or urine concen-
trations of flavan-3-ols metabolites [65]. This observation sug-
gests that inter-individual variation in biological responses is
not solely due to variation in the bioavailability of plant food
bioactives but can depend on other factors, such as sex.
Age is the strongest independent cardiovascular risk fac-
tor for CVD and is also associated with increased vascular
stiffness, endothelial dysfunction and systolic hypertension
[66]. So far, few studies have investigated the impact of age
on the cardiometabolic effects of food bioactives (Table 2).
Consumption of a flavanol-rich drink reversed age-related
increase in systolic blood pressure together with aortic aug-
mentation index (a measure of vascular stiffness) in healthy
elderly but not in young men [67]. In this study, the plasma
levels of flavanol metabolites were not significantly different
between young and elderly individuals, suggesting that dif-
ferences in bioavailability could not explain the differences
observed in biological response [34]. In another intervention
study, the effect of the consumption of a flavanol-rich cocoa
drink on blood pressure was also higher in the elderly than in
young volunteers [68]. An age-dependent effect of quercetin
on blood pressure was also reported [69].
Inter-individual variability in the response to the con-
sumption of plant food bioactives has also been described
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for other phytochemicals (Table 2). For example, despite
the abundance of data of clinical trials demonstrating the
cholesterol-lowering action of plant sterol supplements, sub-
stantial variability in efficacy exists in responsiveness among
individuals [70]. Genetic polymorphisms of genes associated
with cholesterol trafficking processes may be responsible for
this inter-individual variability. For example, a significant
inter-individual variation in the LDL-cholesterol lowering re-
sponse to plant sterol consumption has been associated with
a polymorphism in the ABCG8 gene. The subjects carrying
the A allele of the gene were reported to get a greater benefit
from plant sterol intake [71]. The bioactivity of plant sterols
was also associatedwith polymorphism in cholesterol 7 alpha-
hydroxylase (CYP7A1) gene with -204A>C variant presenting
greater CYP7A1 activity [72].
Environmental factors, including dietary habits, can also
affect our genetic imprint through a range of epigenetic
mechanisms that can impact gene transcription and the sub-
sequent cellular responses. These epigenetic mechanisms
involving DNAmethylation, histone modifications, and non-
coding RNAs (microRNAs, Long noncoding RNAs) regula-
tion emerge as important players in cardiovascular diseases
[73–75]. Recent review papers reported that dietary polyphe-
nols induced epigenetic changes that may promote cardio-
vascular health benefit [19,76]. For example, consumption of
a cocoa extract for two weeks significantly reduced the global
DNA methylation levels of peripheral leukocytes in subjects
with cardiovascular risk factors [77]. Another study demon-
strated that one-year supplementation with a grape extract
containing resveratrol modulated the expression of microR-
NAs involved in the regulation of the inflammatory response
in circulating immune cells of hypertensive male patients
with type 2 diabetes [78]. However, the role of the individual
epigenome in the variation of the responses to plant food
bioactives is still unexplored.
Recently, modest progress has been made toward a better
understanding of the role of genetic polymorphisms in the
variability of the response to diet. For example, the benefit of
the Mediterranean diet (MedDiet) on cardiovascular-related
outcomes was shown to depend on genetic variants of the
Transcription factor 7-like 2 (TCF7L2) gene [79]. This gene
encodes a protein acting as a transcription factor, and the
TCF7L2-rs7903146 polymorphism is known as a strong ge-
netic determinant of type-2 diabetes risk and fasting glucose
concentrations [80]. The prevalence of the 7903146T allele is
associated with higher type-2 diabetes risk. In their study,
Corella et al. showed that an intervention with the MedDiet
was more beneficial toward cardiovascular risk factors and
stroke incidence for individuals with the 7903146T allele [79].
However, it has to be noted that most nutrigenetics studies
thus far are association studies and results have not been
confirmed in studies.
The development of high-throughput “omics” technolo-
gies (epigenomics, metagenomics, transcriptomics, pro-
teomics, metabolomics) and bioinformatic tools has enabled
researchers to go deeper in the analysis of the complex
mechanisms that are involved in the way the organism re-
sponds to plant food bioactives and ultimately impact human
health and well-being. For example, the consumption of hes-
peridin from orange juice or of a resveratrol-containing grape
extract have been shown to change leukocyte gene expres-
sion toward anti-atherogenic and anti-inflammatory profiles
in healthymen [81] and in patients with stable coronary artery
disease [82], respectively. The inter-individual variation in the
overall expression profile of genes involved in the regulation
of cardiometabolic health in response to plant food bioactives
has not been evaluated in humans. However preliminary evi-
dence of a large between-subject variability in the expression
levels of genes and microRNAs related to inflammation and
cardiovascular diseases in humans has been reported [78].
Nutrigenomics, particularly transcriptomic studies, will help
to reveal genes and non-coding RNA expression profiles that
may be used as new biomarkers of responsiveness to plant
food bioactives. Furthermore, investigations focused on the
identification of the molecular mechanisms of action in re-
sponse to plant food bioactives are still necessary to identify
genes and (or) non-codingRNAsunderlying the health effects
of these compounds. These genesmay become candidates for
future nutrigenetic studies aiming to identify gene variants
involved in inter-individual variability in responsiveness to
plant bioactive intake.
In summary, a range of studies have indicated that inter-
individual variation in biological responsiveness to plant food
bioactives exists and that it may be influenced by several
factors including bioavailability and metabolism, gut micro-
biome composition, (epi)-genetic profiles, age, or sex.
1.3 How to tackle the complexity of the
inter-individual variability through a
multi-dimensional approach?
Research in the field of inter-individual variation in response
to consumption of plant bioactives and the determinants in-
volved is presently highly fragmented andmany research gaps
remain. Addressing this question requires the participation
of experts from a range of disciplines. The first initiative to
this end is the creation of a dedicated Action called “FA1403-
POSITIVe” (https://www6.inra.fr/cost-positive) within the
framework of the European Cooperation in Science and
Technology (COST). This open network gathers nutrition-
ists, clinicians, geneticists, epidemiologists, microbiologists,
experts in nutrigenomics, bioinformaticians, molecular biol-
ogists and biochemists from more than 70 research institu-
tions in 31 countries. Their common goal is to analyse in a
systematic way the available knowledge to evaluate the extent
of inter-individual variation for some of the main families
of plant food bioactives and to identify the key determinants
of the inter-individual variation regarding both bioavailability
and bioactivity related to cardiometabolic health outcomes. A
major expected outcome of this COSTAction will be to define
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strategies andmethods to stratify populations into subgroups
according to their ability to respond to plant food bioactives.
From the findings of the POSITIVe network and of other
complementary initiatives, the relative contribution and pos-
sible interactions of themaindeterminants of inter-individual
variability identified should be further validated through dedi-
cated randomized controlled trials and large-scale prospective
studies for the different families of plant food bioactives. The
power of these studies will have to be calculated to allow dif-
ferent ‘responsive’ subgroups analyses and/or wise targeted
recruitmentsmust be performed based on the factors likely to
affect the individual response. In upcoming studies assessing
the health effects of plant foods and their bioactives, publi-
cation of individual data should be strongly recommended
and as far as possible the volunteers should be phenotyped
for the determinants that have already been identified as
important.
Because of the inter-individual variation in ADME, the in-
ternal exposure to plant food bioactive compounds and (or)
derived metabolites is not directly correlated to the dietary
intake and will have to be characterized in depth in future
studies. To date in the vast majority of epidemiological stud-
ies, health outcomes were related to food or nutrient intake
data, estimated fromdietary questionnaires and tables of food
composition without taking into account the bioavailability.
In intervention studies, the background diet and the supple-
mentation are usually standardized but this does not guar-
antee equal internal exposures among volunteers due to the
inter-individual variability in absorption andmetabolizing ca-
pacity. Knownmetabolites can be quantified in biofluids such
as plasma and urine or in tissue biopsies using targetedmeth-
ods of analysis based on UV or mass spectrometry detection.
However, the scope of targeted methods of analysis is usu-
ally restricted to a limited number of known metabolites of a
particular family of compounds. Non-targeted metabolomics
with high-resolution mass spectrometry (Q-TOF and Orbi-
trap instruments) has emerged as a holistic and sensitive ap-
proach to analyse in human biofluids the food metabolome
which encompasses all the metabolites derived from food in-
take and digestion, including the plant food bioactivemetabo-
lites [83, 84]. Comprehensive profiles of metabolites present
in urine, plasma or other biospecimens, including still un-
known metabolites of plant food bioactives, can be obtained
and compared in nutritional intervention studies for subjects
consuming the same diet but stratified according to factors
such as age, sex, gut microbiota composition, and genotype.
The extent and the nature of the differences existing between
the metabolomic profiles of the study groups, for example,
between males and females after the same plant food intake
is likely to provide valuable new insights for a better under-
standing of the inter-individual variation.
Some technological and methodological improvements
will have to be implemented to facilitate the use of
metabolomics for plant food bioactive research. First initia-
tives have been launched in the framework of the COST
Action POSITIVe with the development of a standardized
combination of methods ensuring a wide coverage of plant
foodmetabolites, the sharing of standards of raremetabolites,
and the compilation of metabolism and analytical data in the
online database PhytoHub dedicated to dietary phytochem-
icals (www.phytohub.eu). The objective is to make possible
the use of comprehensive annotated profiles of plant food
bioactive metabolites in intervention trials and large-scale ob-
servational studies such as wide-association studies.
Furthermore, despite the knowledge accumulated on the
metabolism of plant bioactives in humans, and while most
plant biosynthetic pathways of these compounds are accessi-
ble on-line at KEGG (http://www.genome.jp/kegg/pathway.
html) or MetaCyc (http://metacyc.org/) databases, their
metabolic pathways in humans or mammals have not yet
been published in online databases. Up to now, caffeine is the
only plant food bioactive forwhich themetabolism inhumans
is described in the KEGG database (http://www.genome.jp/
kegg/pathway/map/map00232.html). As modern biology in-
creasingly relies on bioinformatics, there is an urgent need to
fill this gap.We need to compile existing knowledge in online
resources, with data on proteins, genes, polymorphisms, gut
bacteria involved as well as to design new research projects
aiming to find out the missing information. In this way,
the updated and complete human metabolic pathways of the
plant bioactive compounds will bemade available for systems
biology approaches to study the inter-individual variability in
an integrative way.
Well-designed intervention and prospective studies, in-
tegrating omics approaches for a better phenotyping of in-
dividuals will show the relative contribution of various fac-
tors to control the bioavailability of different families of plant
food bioactives and the individual biological responsiveness
to their consumption. A major challenge will be to develop
methods and tools to phenotype and stratify individuals based
on their ability to respond to plant food bioactives intake. An
in-depth characterisation of the subjects, including genotyp-
ing, gut microbiota analysis, food metabolome profiling has
become achievable, although still quite expensive, making
feasible the search for correlations between information-rich
datasets and health outcomes in intervention and prospec-
tive studies. New bioactives as well as new molecular tar-
gets in population subgroups may be identified. However,
for the majority of studies investigating the health effects of
plant foods and for clinical applications, the subject strati-
fication methods should be more cost-effective and easy to
handle. Several approaches can be foreseen, including mod-
eling and challenge tests. Models may be built from the ac-
quired knowledge to predict the internal exposure of indi-
viduals based on their declared food intake and their sta-
tus for the main factors controlling inter-individual varia-
tion in ADME (e.g. genotyping and gut microbiota). These
models will be improved as new data and knowledge are
generated and could be validated through measurement of
actual exposure in controlled intervention studies. Together
with models aiming to predict the internal exposure, more
complex ones should also be developed to predict biological
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responsiveness to plant food bioactives intake and thus es-
timate the personal health benefits that an individual can
gain from different bioactives compounds. This estimation
would be made by taking into account the bioavailability of
bioactives together with other factors identified as involved
in the inter-individual variability in responsiveness, such as
age, sex, specific genetic polymorphisms or physiological sta-
tus. Before obtaining enough knowledge to develop such
models, another option for stratification of the population
into responders and non-respondersmay be considered. This
could consist of designing challenge tests in which subjects
would consume a standardized supplement containing var-
ious bioactives. The plasma concentrations and/or urinary
excretion of key metabolites would be monitored according
to a precise sampling schedule over a defined timeframe,
as it has already been proposed for equol-production capacity
[85]. In addition, standardized postprandial nutritionally chal-
lenging conditions could be defined to induce disturbances
impacting cardiometabolic outcomes to assess the individ-
ual capacity to respond to plant food bioactives intake. This
would be done by testing the ability of subjects receiving spe-
cific bioactives to attenuate/counterbalance the induced dis-
turbances by measuring the impact on well-established and
emerging biomarkers of cardiometabolic risk. This challenge
test approach will be helpful both to strengthen the scientific
knowledge of the determinants of inter-individual variability
and to stratify responders/non-responders.
2 Conclusion and perspective
Within the context of improving the health of populations and
promoting sustainable economic growth of the food sector,
research policies emphasize the importance of developing
high quality and healthy foods and refining dietary recom-
mendations to decrease the burden of diet-related chronic
diseases. The challenge is to stimulate both the consumers to
select foods that fit into a healthy diet and the agro-food sector
to develop healthier foods. Dietary patterns rich in plant foods
have been largely shown to be healthier than those rich in ani-
mal products [86]. Consequently, high consumption of fruits,
vegetables and whole-grains is widely encouraged in many
countries through national public health policies. However,
thus far the recommendations are applied to the general pop-
ulation in a “one-size-fits-all approach” without considering
the possible high between-subject variations in response to
plant food bioactives. As a consequence, this approach does
not necessarily ensure adequate exposure to protective com-
pounds for all individuals.
Improving our knowledge of the factors (such as age, sex,
(epi)genotype and gut microbiota) that influence whether
plant food bioactives are more or less effective in individ-
uals, together with the development of methods to identify
responsiveness profiles will be invaluable to progress in the
development of effective and innovative solutions leading
to health improvements. There is a high potential for the
development of new functional foods or optimized tradi-
tional foods with higher effectiveness for general or targeted
populations. For example, adapting processing methods may
improve the bioavailability of key bioactive compounds for
individuals identified as poor absorbers/metabolizers. This
research will also provide the scientific evidence to help the
public health bodies to elaborate a new generation of nu-
tritional recommendations for improving the prevention of
cardiometabolic diseases in the long run. In particular, it
may lead to refined recommendations toward foods partic-
ularly rich in specific bioactives and to public health advice
targeting specific populations. As recently demonstrated in
the European FP7-Food4me project, personalized dietary ad-
vice is more efficient to positively affect dietary behaviours
(see white paper at: www.food4me.org/). In a global context
of an increasing prevalence of low intake of fruits and veg-
etables, with less than 25% of the population consuming at
least five portions per day (400 g) in most countries, more
personalized messages regarding this food group could be
of high benefit [87]. Acquired knowledge might also be in-
tegrated for individual counseling along personal profiles of
determinants affecting the bioavailability and responsiveness
to plant food bioactives.
Addressing the inter-individual variation in response to
plant food bioactives perfectly fits one of the main European
research priorities identified for foods and diets toward 2050,
which is to contribute to the understanding of human vari-
ation in response to nutrition factors and to better translate
this knowledge into innovative individualised food and nutri-
tion solutions to improve citizens’ health [88]. This position
paper elaborated in the framework of the COST POSITIVe
Action proposes some priorities for tackling the challeng-
ing research question of inter-individual variation, with the
ultimate goal of ensuring that the cardiometabolic health-
promoting effects associated with bioactives present in plant
foods are applicable for everyone.
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